Bayer HealthCare Pharmaceuticals Inc. Sustainability Profile
Bayer HealthCare Pharmaceuticals Inc., a prominent division of Bayer AG, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1863, the company has established itself as a leader in the pharmaceutical industry, focusing on areas such as cardiology, oncology, gynaecology, and ophthalmology. Bayer HealthCare is renowned for its innovative products, including prescription medications and over-the-counter solutions that address critical health needs. Its commitment to research and development has led to significant advancements in treatment options, setting it apart in a competitive market. With a strong market position, Bayer HealthCare has achieved numerous accolades for its contributions to healthcare, underscoring its role as a trusted provider of effective and safe pharmaceutical solutions.
DitchCarbon Score
How does Bayer HealthCare Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bayer HealthCare Pharmaceuticals Inc.'s score of 93 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bayer HealthCare Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bayer Aktiengesellschaft, which cascades its climate commitments and emissions data down to its subsidiaries. Bayer Aktiengesellschaft has set ambitious climate targets, including commitments to reduce emissions across its operations. However, specific reduction targets or achievements for Bayer HealthCare Pharmaceuticals Inc. have not been detailed. The company is aligned with various climate initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the parent company level. As part of its corporate family, Bayer HealthCare Pharmaceuticals Inc. benefits from the overarching sustainability strategies of Bayer Aktiengesellschaft, which include efforts to address Scope 1, 2, and 3 emissions. While specific figures for Bayer HealthCare Pharmaceuticals Inc. are not available, the commitment to sustainability and climate action remains a priority within the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | 1,215 | 0,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bayer HealthCare Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Bayer HealthCare Pharmaceuticals Inc.'s Location?
Bayer HealthCare Pharmaceuticals Inc.'s Scope 3 Categories Breakdown
Bayer HealthCare Pharmaceuticals Inc.'s Scope 3 emissions, which decreased by 16% last year and increased significantly since 2004, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 72% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
Bayer HealthCare Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bayer HealthCare Pharmaceuticals Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
